Hospitals have a pathogen problem that spreads invisibly through sinks, ice machines, and scopes - and Claryx has raised $3.5M in pre-seed funding to chase it down at the genetic level. The round was backed by Outlander VC, Company Ventures, Boost VC, NEON, Mana Ventures, 640 Oxford, and Precursor.
Claryx reads the genomes of confirmed patient infections, links related cases as outbreaks, and traces each back to its likely source - often something as mundane as a contaminated surface or a piece of equipment moving between rooms. The company does this against a digital twin of the hospital's microbiome, sequenced from air, water, and surfaces using proprietary chemistry cheap enough to run continuously. Founded by brothers Kurt and Dirk Hackenberger, the New York-based startup is already live across multiple health systems.
